{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:41:31Z","timestamp":1793882491133,"version":"4.7.0"},"reference-count":24,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Upadacitinib is a recently approved Janus kinase (JAK) inhibitor for the treatment of inflammatory bowel disease (IBD). Although it has been adopted for clinical use, there are limited real-world data regarding its efficacy and safety, as well as its effects on laboratory parameters. In our study, we aimed to evaluate these outcomes in patients with moderate-to-severe Crohn\u2019s disease (CD) and ulcerative colitis (UC) who had previously failed biologic agents. Materials and Methods: This retrospective cohort study included 22 UC and 19 CD patients who received Upadacitinib for at least six months, where efficacy was assessed at pretreatment and at 3 and 6 months. We used the Harvey\u2013Bradshaw Index (HBI) for CD and the partial Mayo score (PMS) for UC to define clinical response and remission. Results: All patients were biologic-experienced, with a substantial portion (47%) having previously failed at least two different agents. At six months, the persistence rates were 78.3% for CD and 88% for UC. The clinical response rates were 72.7% for CD and 83.3% for UC, while the clinical remission rates were 50% and 58.3%, respectively. Fecal calprotectin and C-reactive protein levels significantly improved (p &lt; 0.001). Total, LDL, and HDL cholesterol levels increased, but triglyceride levels and the LDL\/HDL ratio remained unchanged. Biochemical parameters, including glucose, HbA1c, and thyroid, kidney, and liver function tests, remained within normal limits. No clinically significant changes were observed in hemogram parameters, and no serious adverse events, embolisms, major cardiovascular events (MACEs), or deaths occurred. Conclusions: Upadacitinib is effective in biologic-unresponsive IBD patients. While it increases cholesterol levels, it does not alter the LDL\/HDL ratio and does not demonstrate a negative effect on glucose metabolism. Further multicenter, longer-term studies are needed on this topic.<\/jats:p>","DOI":"10.3390\/medicina61091692","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:32:32Z","timestamp":1758187952000},"page":"1692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Upadacitinib in Biologic-Experienced Inflammatory Bowel Disease: Real-World Efficacy, Safety, and Laboratory Outcomes"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8299-5341","authenticated-orcid":false,"given":"Osman","family":"\u00d6zdo\u011fan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine (Gastroenterology), Faculty of Medicine, Mersin University, 33343 Mersin, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-7515","authenticated-orcid":false,"given":"Serkan","family":"Yara\u015f","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Gastroenterology), Faculty of Medicine, Mersin University, 33343 Mersin, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: Past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomized trial","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn\u2019s disease: A UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Frontline Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"jjaf095","DOI":"10.1093\/ecco-jcc\/jjaf095","article-title":"Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: A post hoc analysis of phase 3 trial data","volume":"19","author":"Dubinsky","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_6","unstructured":"Drugs.com (2012, November 06). FDA Approves Xeljanz for Rheumatoid Arthritis. Available online: https:\/\/www.drugs.com\/newdrugs\/fda-approves-xeljanz-rheumatoid-arthritis-3558.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1759720X231201047","DOI":"10.1177\/1759720X231201047","article-title":"Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: A post hoc analysis of ORAL Surveillance","volume":"15","author":"Karpouzas","year":"2023","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/RHU.0000000000002106","article-title":"Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients with Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study","volume":"30","author":"Citera","year":"2024","journal-title":"J. Clin. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: A comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_11","first-page":"154","article-title":"Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases\u2014A meta-analysis of randomized controlled trials","volume":"44","author":"Falcon","year":"2025","journal-title":"Indian. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40261-024-01364-0","article-title":"Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn\u2019s Disease and Ulcerative Colitis","volume":"44","author":"Niu","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular, and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn\u2019s Disease: Prospective Real-World Experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/apt.70199","article-title":"Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study","volume":"62","author":"Osty","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","first-page":"181","article-title":"An overview of lipid abnormalities in patients with inflammatory bowel disease","volume":"24","author":"Agouridis","year":"2011","journal-title":"Ann. Gastroenterol."},{"key":"ref_17","first-page":"39","article-title":"Pharmacology and safety of tofacitinib in ulcerative colitis","volume":"44","author":"Esplugues","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Charles-Schoeman, C.G., Giles, J.T., Lane, N.E., Choy, E., Camp, H., Song, Y., Anyanwu, S., and McInnes, I. (2020). Relationship between changes in lipid levels and improvement in disease activity outcomes in patients with rheumatoid arthritis receiving upadacitinib treatment: Pooled analysis of data from two Phase 3 studies [Abstract]. Arthritis Rheumatol., 72, Available online: https:\/\/acrabstracts.org\/abstract\/relationship-between-changes-in-lipid-levels-and-improvement-in-disease-activity-outcomes-in-patients-with-rheumatoid-arthritis-receiving-upadacitinib-treatment-pooled-analysis-of-data-from-two-phase\/.","DOI":"10.1136\/annrheumdis-2021-eular.606"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Makris, A., Barkas, F., Sfikakis, P.P., Liberopoulos, E., and Agouridis, A.P. (2022). The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 11.","DOI":"10.3390\/jcm11236894"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Martinez-Molina, C., Diaz-Torne, C., Park, H.S., Feliu, A., Vidal, S., and Corominas, H. (2024). Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis. Medicina, 60.","DOI":"10.3390\/medicina60030360"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wu, H., Xie, T., Yu, Q., Su, T., Zhang, M., Wu, L., Wang, X., Peng, X., Zhi, M., and Yao, J. (2025). An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010190"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: Final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:41Z","timestamp":1760035661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/9\/1692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["medicina61091692"],"URL":"https:\/\/doi.org\/10.3390\/medicina61091692","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}